Shionogi extends MorphoSys partnership
This article was originally published in Scrip
Executive Summary
Shionogihas extended a 2005 licensing agreement for the use of MorphoSys's HuCAL technology in its drug discovery programmes for three years. The Japanese firm has the right to access MorphoSys's HuCAL GOLD library of proprietary, fully humanised antibodies at one site in Japan in return for annual fee payments to the German firm.